

## Disclosures

### Personal Commercial (51)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott Laboratories	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Alnylam	Research/Research Grants	Significant (>= \$5,000)	Other
Alnylam	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Amgen Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Analog Medical Devices	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Anthos Therapeutics	Consultant Fees/Honoraria	Significant (>= \$5,000)	Vascular Medicine
Anumana/nference	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
AstraZeneca Pharmaceuticals	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Avalyn Pharma	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Avania Clinical Research	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Avidity Biopharma	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Axon Therapeutics	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Baim Clinical Research Institute	Other - Adjudicator for CEC	Significant (>= \$5,000)	General Cardiology
Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Bayer Healthcare Pharmaceuticals	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Biofourmis	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Boston Scientific	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
ClinChoice	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Colorado Prevention Center	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Corsera Health	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
CVS Caremark	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Cytokinetics	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
DevPro Biopharma	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Duke Clinical Research Institute	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Edwards Lifesciences	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Eli Lilly and Company	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Endotronix	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
FIRE1 Foundry	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
GlaxoSmithKline	Consultant Fees/Honoraria	Significant (>= \$5,000)	Other
ICON Clinical Research	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
iRhythm Technologies	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Medpace	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
Medtronic	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Merck & Co., Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
New Amsterdam	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">General Cardiology</a>
Novartis Corporation	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Novartis Corporation	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Parexel	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Pfizer Inc	Research/Research Grants ‡ GARDEN TIMI-75	None (\$0)	<a href="#">Heart Failure and Cardiomyopathies</a>
Pharmacosmos	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Regeneron	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
River2Renal	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Roche	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">General Cardiology</a>
scPharma	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Stanford Clinical Research Institute	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Teva	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
TIMI Study Group	Other - Adjudication for CEC	Significant (>= \$5,000)	<a href="#">General Cardiology</a>
Vectorious Medical Technologies	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Verve Therapeutics	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Volta medical	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>

## Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

## Personal Organizational or Other Non-Commercial (1)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
DTX Plus, Inc	Ownership Interest/Partnership/Principal	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>

## Clinical Trial Enroller (1)

Trial Name	Trial Sponsor	Trial Funding Source
ALLAY-HF	Alleviant Medical	

## Institutional Financial Decision-Making Role (0)

No disclosures on record

## Expert Witness Testimony (3)

Year	Case Title	Represented	Description	Compensation
<b>Self</b>				
2026	Endocarditis	Plaintiff	Delay in care related to failure to diagnose endocarditis	Significant (>= \$5,000)
2019	Cardiomyopathy	Defendant	Failure to diagnose and treat hemochromatosis involving the heart	Modest (< \$5,000)
2018	Out of Hospital Cardiac Arrest	Plaintiff	Failure to defibrillate patient with available AED during out of hospital arrest	Modest (< \$5,000)

‡ Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation | Signed on 4/6/2026

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

### Confidentiality, Disclosure and Assignment Agreement | Signed on 4/6/2026

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

### Embargo | Signed on 4/6/2026

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

## **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.